Clinical trials in Roubaix – page 6

1 745 clinical trials in Roubaix, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Roubaix at a glance

1 745

clinical trials

Research sites1

Quick filters

1 745 trials in Roubaix

Open in trial search

Hepatic cirrhosis+2

Recruiting

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational

France

Participants:18–64 years · 65+ years
Substances:Efruxifermin
Sponsor:Akero Therapeutics Inc.

Contact Research Centre

Amyotrophic lateral sclerosis

Recruiting

Study on the Safety and Effectiveness of Dazucorilant for Patients with Amyotrophic Lateral Sclerosis (ALS)

Investigational

Study on the Safety and Effectiveness of Dazucorilant for Patients with Amyotrophic Lateral Sclerosis (ALS)

Investigational

France

Participants:18–64 years · 65+ years
Substances:Dazucorilant
Sponsor:Corcept Therapeutics Inc.

Contact Research Centre

Breast cancer

Recruiting

Study of Tersolisib and a drug combination for adults with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Registered drug

Study of Tersolisib and a drug combination for adults with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:Eli Lilly & Co.

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Efficacy and Safety of Three Different Doses of Pirtobrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Previously Received BTK Inhibitor Treatment

InvestigationalNo placebo

Efficacy and Safety of Three Different Doses of Pirtobrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Previously Received BTK Inhibitor Treatment

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Pirtobrutinib
Sponsor:Eli Lilly & Co.

Contact Research Centre

Non-small cell lung cancer metastatic

Recruiting

First-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab

Registered drugNo placebo

First-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ivonescimab
Sponsor:Summit Therapeutics Inc.

Contact Research Centre

Dementia Alzheimer's type

Recruiting

Efficacy and Safety of RO7568282 in Adults with Early Symptomatic Alzheimer’s Disease

Investigational

Efficacy and Safety of RO7568282 in Adults with Early Symptomatic Alzheimer’s Disease

Investigational

France

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Interstitial lung disease

Recruiting

Efficacy and Safety of BI 1015550 in Adults with Fibrosing Interstitial Lung Disease at Risk of Disease Progression: A Randomized, Placebo‑Controlled Trial

Investigational

Efficacy and Safety of BI 1015550 in Adults with Fibrosing Interstitial Lung Disease at Risk of Disease Progression: A Randomized, Placebo‑Controlled Trial

Investigational

France

Participants:18–64 years · 65+ years
Substances:Nerandomilast
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Small cell lung cancer extensive stage

Recruiting

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Siltuximab
Sponsor:Amgen Inc.

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

France

Participants:18–64 years · 65+ years
Substances:PIPE-791
Sponsor:Contineum Therapeutics Inc.

Contact Research Centre

Gastrointestinal stromal tumour

Recruiting

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Imatinib Mesilate
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Daraxonrasib
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Ductal adenocarcinoma of pancreas

Recruiting

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational

France

Participants:18–64 years · 65+ years
Substances:ASP3082
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Roubaix

What the registry says about research in the country

01 Hematologic Oncology

Research focusing on innovative treatments for Multiple Myeloma and various forms of leukemia, including comparative studies of novel therapeutic combinations and traditional approaches.

Multiple Myeloma therapies
Acute Myeloid Leukemia treatments
Myeloproliferative disorders

Studies evaluating treatment effectiveness in newly diagnosed patients and those with advanced disease stages.

02 Neurological Disorders

Innovative research exploring potential treatments for Alzheimer's disease, including studies on caffeine's effects on cognitive function in early-to-moderate stage patients.

Cognitive decline prevention
Novel therapeutic approaches
Disease progression monitoring

Focus on non-pharmacological interventions and their impact on disease progression.

03 Respiratory Medicine

Clinical investigations into severe asthma management and pulmonary infections, including studies on treatment optimization and novel therapeutic approaches.

Severe allergic asthma control
Mycobacterium avium complex treatment
Medication withdrawal studies

Evaluation of long-term treatment strategies and comparative medication studies.

04 Cardiovascular and Renal Studies

Research examining hypertension management in patients with chronic kidney disease, along with studies on thrombo-embolic complications prevention.

Blood pressure management
Kidney disease progression
Cardiovascular risk reduction

Focus on optimizing treatment strategies for complex cardiovascular conditions.

Back to France All countries